Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 6 sources · 12 days · First seen · Last updated
Corporate financial results and market performance
Overview
In August 2026, several companies reported significant financial results and market movements.
Kuros Group (also referred to as Kuros Biosciences) reported a strong first half of 2026, achieving its first historical net profit of $4.4 million. This was driven by a 45 percent increase in revenue to $92.4 million, fueled by market share gains in orthobiologics. Despite this growth, the company’s stock experienced a 6.1 percent decline due to profit-taking.
On Holding AG reported record revenue of 850 million Swiss francs, a 13.5 percent increase from the previous year. However, the company missed analyst expectations of approximately 880 million francs, and growth in the US market slowed to 13 percent. This led to a 20 percent drop in its Wall Street stock price to $31.91.
Other notable market activities included Lam Research exceeding revenue expectations due to the AI boom, Cabot Corporation issuing $350 million in new bonds, and gains in biotechnology stocks such as Corbus Pharmaceuticals and CRISPR Therapeutics.
Entities
Intismeran autogene · Wall Street · Corbus Pharmaceuticals · On Holding AG · Cabot Corporation
Timeline
-
1 day ago
[HEALTH] 6 sourcesModerna and Merck report breakthrough in personalized mRNA cancer vaccine trialModerna and Merck report successful Phase 3 results for a personalized mRNA melanoma vaccine, significantly reducing cancer recurrence risk and triggering a massive surge in biotech stocks.
-
13 days ago
[BUSINESS] 4 sourcesOn Holding and Kuros report divergent financial resultsSwiss firms On Holding AG and Kuros Group reported mixed results: On saw a 20% stock drop despite record revenue, while Kuros achieved its first profit and confirmed annual growth targets.
Sources
ad-hoc-news.de · elnorte.com.co · genengnews.com · newsin.ro · thepodiummedia.com · tribuneonlineng.com